Feature

Conavi’s recent RTO fuels trajectory of world’s first and only hybrid intravascular imaging system combining co-registered IVUS + OCT

Conavi Medical (TSXV:CNVI) is leveraging its recent reverse merger (RTO) with Titan Medical to accelerate the wide-spread adoption of its breakthrough imaging platform, the next-generation Novasight Hybrid System...

November 5, 2024

Feature

Creyon Bio reimagining drug development with engineered on-demand oligonucleotide therapies

Closely-held Creyon Bio is developing a faster, more cost-effective path to new medicines for rare and common diseases through the AI-enabled engineering of oligonucleotide-based therapies (OBMs) that deliver safe...

October 15, 2024

Feature

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) is developing and partnering therapies to control the immune system for immuno-oncology (IO) and immuno-inflammation with first-in-class immunotherapies from target...

October 1, 2024

Feature

InfoBionic.Ai innovating a beat ahead with gold standard remote cardiac care

Closely-held InfoBionic.Ai, a pioneering virtual cardiac telemetry company, is transforming cardiac patient care by equipping healthcare providers with a sophisticated ecosystem of solutions designed to enhance every...

September 17, 2024

NEWS

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Conavi’s recent RTO fuels trajectory of world’s first and only hybrid intravascular imaging system combining co-registered IVUS + OCT

Creyon Bio reimagining drug development with engineered on-demand oligonucleotide therapies

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

InfoBionic.Ai innovating a beat ahead with gold standard remote cardiac care

NEWS

Alterity underscores published data on role of iron in neurodegenerative diseases

BioRestorative to unveil key Phase 2 findings on BRTX-100 for cLDD at ORS PSRS International Spine Research Symposium

ZyVersa highlights published data supporting potential of IC 100 for obesity care

Transgene and ProBioGen partner to advance cancer vaccine development

Essa terminates Phase 2 study of Masofaniten combined with Enzalutamide in mCRPC

FDA grants Type C meeting with Kazia on next steps for Paxalisib in GBM

OSE announces positive Phase 2 results of Lusvertikimab for UC

Lifecore appoints Thomas Guldager as VP operations, names Jackie Klecker as EVP quality

Profound’s 2025 TULSA CMS reimbursement level leapfrogs all other prostate disease modalities

Just a few of the companies we’ve highlighted along the way

General

More